Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.31 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.31 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.31 |
| ▸ | ITGAV | P06756 | 1/20 | 0.31 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.31 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.31 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.31 |
| ▸ | ITGAL | P20701 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13435368 | 1.00 | ITGB3 (0.31) | ITGB3ITGB2ITGB1ITGAVITGA2B | |
| SCHEMBL12572124 | 1.00 | ITGB3 (0.31) | ITGB3ITGB2ITGB1ITGAVITGA2B | |
| SCHEMBL25043983 | 0.85 | CAD (0.40) | ITGB3ITGB2ITGB1ITGAVITGA2B | |
| SCHEMBL23260109 | 0.85 | CAD (0.40) | ITGB3ITGB2ITGB1ITGAVITGA2B | |
| SCHEMBL24928556 | 0.85 | CAD (0.40) | ITGB3ITGB2ITGB1ITGAVITGA2B | |
| SCHEMBL12236182 | 0.83 | APEX1 (0.33) | — | |
| SCHEMBL26723885 | 0.77 | TOP2A (0.37) | — | |
| SCHEMBL13611121 | 0.75 | PRKCA (0.40) | — | |
| SCHEMBL13435401 | 0.74 | ITGB1 (0.36) | ITGB3ITGB2ITGB1ITGAVITGA2B | |
| SCHEMBL8232195 | 0.74 | P2RX7 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100075895-A1 | Cyclic Natriuretic Peptide Constructs | PALATIN TECHNOLOGIES, INC. (US) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075895-A1 | Cyclic Natriuretic Peptide Constructs | NPR1, NPR3, NPPA | ITGB3 3857/4885ITGB2 4125/4885ITGB1 4228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.